FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121009990> ?p ?o ?g. }

• W3121009990 endingPage "594" @default.
• W3121009990 startingPage "585" @default.
• W3121009990 abstract "Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic analysis indicates that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis at high risk of fracture. To estimate the cost-effectiveness of sequential treatment with romosozumab followed by alendronate (“romosozumab-to-alendronate”) compared with alendronate alone in patients with severe osteoporosis at high risk of fracture in Sweden. A microsimulation model with a Markov structure was used to simulate fractures, costs, and quality-adjusted life years (QALYs), for women treated with romosozumab-to-alendronate or alendronate alone. Patients aged 74 years with a recent major osteoporotic fracture (MOF) were followed from the start of treatment until the age of 100 years or death. Treatment with romosozumab for 12 months was followed by alendronate for up to 48 months or alendronate alone with a maximum treatment duration of 60 months. The analysis had a societal perspective. Efficacy of romosozumab and alendronate were derived from phase III randomized controlled trials. Resource use and unit costs were collected from the literature. Cost-effectiveness was estimated using incremental cost-effectiveness ratio (ICER) with QALYs as effectiveness measures. The base case analysis showed that sequential romosozumab-to-alendronate treatment was associated with 0.089 additional QALYs at an additional cost of €3002 compared to alendronate alone, resulting in an ICER of €33,732. At a Swedish reference willingness-to-pay per QALY of €60,000, romosozumab-to-alendronate had a 97.9% probability of being cost-effective against alendronate alone. The results were most sensitive to time horizon, persistence assumptions, patient age, and treatment efficacy. The results of this study indicate that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis at high risk of fracture." @default.
• W3121009990 created "2021-01-18" @default.
• W3121009990 creator A5007547870 @default.
• W3121009990 creator A5019982183 @default.
• W3121009990 creator A5023162226 @default.
• W3121009990 creator A5024756058 @default.
• W3121009990 creator A5040836181 @default.
• W3121009990 creator A5060150960 @default.
• W3121009990 creator A5069035143 @default.
• W3121009990 creator A5081966302 @default.
• W3121009990 creator A5087726384 @default.
• W3121009990 date "2021-01-06" @default.
• W3121009990 modified "2023-10-12" @default.
• W3121009990 title "Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden" @default.
• W3121009990 cites W1128925028 @default.
• W3121009990 cites W1499726145 @default.
• W3121009990 cites W1539664312 @default.
• W3121009990 cites W1789637994 @default.
• W3121009990 cites W1966813919 @default.
• W3121009990 cites W1976384386 @default.
• W3121009990 cites W1986913997 @default.
• W3121009990 cites W1990771263 @default.
• W3121009990 cites W1994955754 @default.
• W3121009990 cites W1996926816 @default.
• W3121009990 cites W2007965843 @default.
• W3121009990 cites W2015350578 @default.
• W3121009990 cites W2025881993 @default.
• W3121009990 cites W2047219483 @default.
• W3121009990 cites W2050587934 @default.
• W3121009990 cites W2052113230 @default.
• W3121009990 cites W2099042805 @default.
• W3121009990 cites W2106406207 @default.
• W3121009990 cites W2107177524 @default.
• W3121009990 cites W2110022366 @default.
• W3121009990 cites W2124147605 @default.
• W3121009990 cites W2157376642 @default.
• W3121009990 cites W2487232386 @default.
• W3121009990 cites W2565810605 @default.
• W3121009990 cites W2587229819 @default.
• W3121009990 cites W2754720807 @default.
• W3121009990 cites W2807903279 @default.
• W3121009990 cites W2911959853 @default.
• W3121009990 cites W2973632969 @default.
• W3121009990 cites W3006027916 @default.
• W3121009990 cites W3040343646 @default.
• W3121009990 cites W3118646243 @default.
• W3121009990 doi "https://doi.org/10.1007/s00198-020-05780-8" @default.
• W3121009990 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7929944" @default.
• W3121009990 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33409591" @default.
• W3121009990 hasPublicationYear "2021" @default.
• W3121009990 type Work @default.
• W3121009990 sameAs 3121009990 @default.
• W3121009990 citedByCount "25" @default.
• W3121009990 countsByYear W31210099902021 @default.
• W3121009990 countsByYear W31210099902022 @default.
• W3121009990 countsByYear W31210099902023 @default.
• W3121009990 crossrefType "journal-article" @default.
• W3121009990 hasAuthorship W3121009990A5007547870 @default.
• W3121009990 hasAuthorship W3121009990A5019982183 @default.
• W3121009990 hasAuthorship W3121009990A5023162226 @default.
• W3121009990 hasAuthorship W3121009990A5024756058 @default.
• W3121009990 hasAuthorship W3121009990A5040836181 @default.
• W3121009990 hasAuthorship W3121009990A5060150960 @default.
• W3121009990 hasAuthorship W3121009990A5069035143 @default.
• W3121009990 hasAuthorship W3121009990A5081966302 @default.
• W3121009990 hasAuthorship W3121009990A5087726384 @default.
• W3121009990 hasBestOaLocation W31210099901 @default.
• W3121009990 hasConcept C112930515 @default.
• W3121009990 hasConcept C126322002 @default.
• W3121009990 hasConcept C2776541429 @default.
• W3121009990 hasConcept C3019080777 @default.
• W3121009990 hasConcept C64332521 @default.
• W3121009990 hasConcept C71924100 @default.
• W3121009990 hasConceptScore W3121009990C112930515 @default.
• W3121009990 hasConceptScore W3121009990C126322002 @default.
• W3121009990 hasConceptScore W3121009990C2776541429 @default.
• W3121009990 hasConceptScore W3121009990C3019080777 @default.
• W3121009990 hasConceptScore W3121009990C64332521 @default.
• W3121009990 hasConceptScore W3121009990C71924100 @default.
• W3121009990 hasFunder F4320307105 @default.
• W3121009990 hasFunder F4320337846 @default.
• W3121009990 hasIssue "3" @default.
• W3121009990 hasLocation W31210099901 @default.
• W3121009990 hasLocation W31210099902 @default.
• W3121009990 hasOpenAccess W3121009990 @default.
• W3121009990 hasPrimaryLocation W31210099901 @default.
• W3121009990 hasRelatedWork W1964369540 @default.
• W3121009990 hasRelatedWork W1977122543 @default.
• W3121009990 hasRelatedWork W1988580400 @default.
• W3121009990 hasRelatedWork W2001074839 @default.
• W3121009990 hasRelatedWork W2008127256 @default.
• W3121009990 hasRelatedWork W2078207681 @default.
• W3121009990 hasRelatedWork W2109316890 @default.
• W3121009990 hasRelatedWork W2527914130 @default.
• W3121009990 hasRelatedWork W2976142964 @default.
• W3121009990 hasRelatedWork W2531417675 @default.
• W3121009990 hasVolume "32" @default.
• W3121009990 isParatext "false" @default.

• next